2021 DORIS definition of remission in SLE: Final recommendations from an international task force
- Ronald F. van Vollenhoven,
- George Bertsias,
- Andrea Doria,
- David Isenberg,
- Eric Morand,
- Michelle A. Petri
- Amsterdam Rheumatology and Immunology Center,
- University Hospital of Heraklion,
- University of Padova,
- University College London,
- Monash Medical Centre,
- Johns Hopkins University School of Medicine
Open access
Publication Information
Output type
Original language
EnglishArticle number
e000538Journal (Volume, Issue Number)
Lupus Science and Medicine (Volume 8, Issue 1)Publication milestones
- Published - 24/11/2021
Publication status
Publication IDs
- Scopus: 85121234911
Abstract
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
